About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PREVENT Tool Study: Late Effects Clinic | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT04530825

PREVENT Tool Study: Late Effects Clinic

The purpose of this study is to test the feasibility of a novel, Health Information Technology behavior change tool in a single clinic setting. The PREVENT tool is the first electronic health record (...

Lead sponsor: Washington University School of Medicine•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Washington University School of Medicine

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Age

12 - 19 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patient Eligibility Criteria:
•Adolescents 12 to 19 years
•Prior diagnosis of pediatric cancer (diagnosed \<21 years of age)
•Not receiving active therapy for their cancer
•Receiving care from the Pediatric Hematology/Oncology staff and physicians at St. Louis Children's Hospital or the St. Louis Children's Specialty Care Center (CSCC)
•At risk for poor cardiovascular health (CVH) (BMI greater than or equal to 85th percentile)
•Provider Eligibility Criteria -All providers and staff (physicians, nurses, clinic staff, clinical research associates) in the Pediatric Hematology/Oncology program at St. Louis Children's Hospital and the CSCC
•Parent Eligibility Criteria
•A parent or legal guardian of a study participant. The parent or legal guardian must have been present at the clinic visit in which the PREVENT tool was administered to the study participant.

Related studies

Health Ahead Comparative Effectiveness Study

NCT07669168 · Health Services Accessibility, Rural Health, and more

RECRUITINGPhase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012 · Cardiovascular Disease

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249 · Cardiovascular Diseases

Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany

NCT06675552 · Heart Disease, Heart Failure, and more

RECRUITINGPhase 3

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294 · Atherosclerosis, Cardiovascular Diseases, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 25, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment65

Start dateFeb 2021

Last updatedApr 25, 2023

Condition

Cardiovascular Disease Childhood Obesity

Locations shown

Washington University School of Medicine

St Louis, Missouri

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 25, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions